Hi-P International is a leader in the advanced manufacturing sector. Headquartered in Singapore, Hi-P provides best-in-class one-stop advanced manufacturing capabilities and services to a diverse and high-quality customer base, comprising leading global players in the consumer goods and electronics, e-commerce, electric automotive and medical devices industries. Hi-P’s global manufacturing footprint encompasses multiple manufacturing plants across various jurisdictions including in China (Shanghai, Chengdu, Xiamen, Suzhou and Nantong), Singapore, Philippines, Vietnam, Malaysia, India and Thailand. It has also established marketing and engineering offices in China, Singapore, Taiwan, Germany and the USA.

Who we partnered with

65 Equity Partners is working alongside Executive Chairman and Founder, Mr Yao Hsiao Tung, a successful entrepreneur who has led Hi-P’s evolution, as well as its experienced management team, to support Hi-P’s growth.

What attracted us to the business

We are attracted to Hi-P’s established market position and robust track record as one of the leading advanced manufacturers in Asia, with a diverse blue-chip customer portfolio, many of whom are among the top global players in their respective industries. With its extensive Asian presence, Hi-P is well-positioned to capitalise on the increasingly fragmented supply chain.

Our value creation strategy

We aim to leverage our expertise and global network to support Hi-P’s management team in strengthening its corporate governance and leadership development strategies as Hi-P works towards an eventual public listing. We will also work closely with the management team on a wide range of organic and inorganic growth initiatives.

Website

https://www.hi-p.com

TDConnex is a leading global precision manufacturer which provides cutting-edge engineering and manufacturing services to global technology leaders. Founded initially as a subsidiary business unit of the Tongda Group, a Hong-Kong based diversified conglomerate listed on the Stock Exchange of Hong Kong, TDConnex’s leading-edge, micro-precision components can be found in over a billion technology products worldwide today. Post-investment, TDConnex has been carved out as a newly independent company headquartered in Singapore, with independent operations, profitability, and a strong set of global leaders as customers. It has production sites in both China and India.  

Who we partnered with?

65 Equity Partners partnered with (i) TDConnex’s CEO Thanga Venkatachalam and his senior management team, and (ii) Novo Tellus Capital Partners, a Singapore-based private equity firm specializing in the mid-market technology and industrial sectors, in the acquisition of 100% of TDConnex to support its continued pursuit of manufacturing excellence to serve global technology leaders.

What attracted us to the business?

We are attracted to TDConnex’s differentiated, market-leading and comprehensive engineering capabilities and its strong track record of manufacturing excellence. It is well-positioned to capitalize on secular tailwinds from global supply chain evolution, together with attractive end market demand driven by continued trends towards miniaturization, premiumization and the Internet of Things (IoT).

Our value creation strategy

Partnering with the management team of TDConnex and Novo Tellus, we aim to leverage our local and international footprint to support the business in accessing new markets, deepening supply chain and new product development. We also aim to work closely with the management team on a wide range of organic and inorganic growth initiatives.

Website

https://www.tdconnex.com

65 Equity Partners has invested in Tamarind Health Limited (“Tamarind Health”), a premier oncology and cardiology group in Asia, encompassing the medical practices set out below.

OncoCare Medical (“OncoCare”) is one of the largest private oncology practices in Singapore, providing comprehensive consulting, diagnosis, and treatment services across various subspecialties.

Novena Heart Centre (“NHC”) is one of the leading multi-disciplinary cardiology group practices in Singapore, specializing in coronary intervention, heart rhythm management, heart failure, cardiac imaging, and cardiothoracic surgery.

Since our investment in the Platform, the Platform has further acquired 4 other assets, including Icon Cancer Centre Hong Kong (“Icon HK”), Singapore Breast Surgery Center (“SBSC”), Central Luzon Integrated Oncology Centre (“CLIOC”) and Can-Care.

Icon HK is a premium oncology cancer centre group in Hong Kong, providing a full suite of oncology services across various cancer types, including medical oncology, radiation oncology, wholesale pharmacy, and colorectal surgical services.

SBSC is an integrated breast cancer care group in Singapore, operating under the brands Solis and Luma, covering the entire breast cancer theragnostic process, including screening, diagnostic imaging, pathology and surgery services.

CLIOC is a leading oncology clinic located in Mother Teresa of Calcutta Medical Center in San Fernando, Philippines, providing tomotherapy and chemotherapy services.

Can-Care is a retailer and distributor of post-cancer care products, operating out of four retail outlets in Singapore and Malaysia, as well as 22 distributor outlets in various jurisdictions.

Who we partnered with

65 Equity Partners partnered with Templewater, a Hong Kong-based private equity firm, on the establishment of the Platform and its initial acquisition of OncoCare and NHC. 65 Equity Partners is dedicated to collaborating closely with doctors and management to maintain the Platform’s high standards and support its international expansion.

What attracted us to the business

The Platform has quality business fundamentals stemming from its market leading practices and specialists. It is well-positioned to capitalize on the regional secular tailwinds of an aging population, the rise in private healthcare spending, and Singapore’s status as a leading medical hub. We are excited about the opportunity to work with our shareholder partner and doctors to grow the group into a leading regional healthcare platform headquartered in Singapore. 

Our value creation strategy

We aim to leverage our connections in the Singapore and Southeast Asia healthcare sector as well as our international market access to support both organic and inorganic growth initiatives, to enhance operations, and to build a leading specialty healthcare platform delivering best-in-class healthcare services to an even broader patient base in the region.

Website

https://oncocare.sg/

https://www.novenaheartcentre.com.sg/